Abstract
Background: Since publication of ACOSOG Z0011 trial, the standard of care of early-stage breast cancer patients with 1–2 positive sentinel lymph nodes (SLN) is to avoid completion of node dissection, assuming the risk of leaving additional positive non-SLN in 27% patients without a detrimental effect on their disease free survival (DFS) or overall survival (OS).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
